Limited effects of β-endorphin compared to loperamide or fentanyl in a neuroendocrine biomarker assay in non-human primates

Psychoneuroendocrinology

Volumn 33, Issue 3, 2008, Pages 292-304

  Butelman, Eduardo R ^a   Reed, Brian ^a   Chait, Brian T ^a   Mandau, Marek ^a   Yuferov, Vadim ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Endorphin; Biomarker; Loperamide; Macaca; Opioid; Prolactin

Indexed keywords

BETA ENDORPHIN; BIOLOGICAL MARKER; FENTANYL; LOPERAMIDE; NEUROPEPTIDE; PROLACTIN;

ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG EFFECT; IN VIVO STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEUROENDOCRINE SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMATE; PRIORITY JOURNAL; PROLACTIN RELEASE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANALGESICS, OPIOID; ANIMALS; ANTIDIARRHEALS; BETA-ENDORPHIN; BIOLOGICAL MARKERS; BIOTRANSFORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FENTANYL; INJECTIONS, INTRAVENOUS; LOPERAMIDE; MACACA MULATTA; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NEUROSECRETORY SYSTEMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 39049109501     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2007.11.011     Document Type: Article

References (61)

1. Alt A., Mansour A., Akil H., Medzihradsky F., Traynor J.R., and Woods J.H. Stimulation of guanosine-5′-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. J. Pharmacol. Exp. Ther. 286 (1998) 282-288
2. Armstrong W.E., and Hatton G.I. The localization of projection neurons in the rat hypothalamic paraventricular nucleus following vascular and neurohypophysial injections of HRP. Brain Res. Bull. 5 (1980) 473-477
3. Babu C.V., Lho D.S., and Yoo Y.S. Monitoring the neuropeptide metabolites by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J. Pharm. Biomed. Anal. 23 (2006) 136-141
4. Barr C.V., Schwandt M., Lindell S.G., Chen S.A., Goldman D., Suomi S.J., Higley J.D., and Heilig M. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus monkeys. Arch. Gen. Psychiatry 64 (2007) 369-376
5. Bart G., Kreek M.J., Ott J., LaForge K.S., Proudnikov D., Pollak L., and Heilig M. Increased attributable risk related to a functional mu-opioid polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30 (2005) 417-422
6. Beauvillain J.C., Moyse E., Dutriez I., Mitchell V., Poulain P., and Mazzucca M. Localization of mu opioid receptors on the membranes of nerve endings and tanycytes in the guinea-pig median eminence by electron microscopic radioautography. Neuroscience 49 (1992) 925-936
7. Bero L.A., Lurie S.N., and Kuhn C.M. Early ontogeny of kappa-opioid receptor regulation of prolactin secretion in the rat. Brain Res. 465 (1987) 189-196
8. Beyer A., Koch T., Schroder H., Schulz S., and Hollt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J. Neurochem. 89 (2004) 553-560
9. Blackford S.P., Little P.J., and Kuhn C.M. Mu- and kappa-opiate receptor control of prolactin secretion in rats: ontogeny and interaction with serotonin. Endocrinology 131 (1992) 2891-2897
10. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., and Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. USA 95 (1998) 9608-9613
11. Bowen C.A., Negus S.S., Kelly M., and Mello N.K. The effects of heroin on prolactin levels in male rhesus monkeys: use of cumulative dosing procedures. Psychoneuroendocrinology 27 (2002) 319-336
12. Brown N.A., and Bethea C.L. Cloning of decidual prolactin from rhesus macaque. Biol. Reprod. 50 (1994) 543-552
13. Butelman E.R., Harris T.J., and Kreek M. Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur. J. Pharmacol. 383 (1999) 305-309
14. Butelman E.R., Harris T.J., and Kreek M.J. Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys. Psychopharmacology (Berlin) 147 (1999) 73-80
15. Butelman E.R., Ball J.W., and Kreek M.J. Comparison of the discriminative and neuroendocrine effects of centrally-penetrating kappa-opioid agonists in rhesus monkeys. Psychopharmacology 164 (2002) 115-120
16. Butelman E.R., Ball J.W., and Kreek M.J. Peripheral selectivity and apparent efficacy of dynorphins: comparison to non-peptidic kappa-opioid agonists in rhesus monkeys. Psychoneuroendocrinology 29 (2004) 307-326
17. Caldara R., Testori G.P., Ferrari C., Romussi M., Rampini P., Borzio M., and Barbieri C. Effect of loperamide, a peripheral opiate agonist, on circulating glucose, free fatty acids, insulin, C-peptide and pituitary hormones in healthy man. Eur. J. Clin. Pharmacol. 21 (1981) 185-188
18. Catlin D.H., Poland R.E., Gorelick D.A., Gerner R.H., Hui K.K., Rubin R.T., and Li C.H. Intravenous infusion of beta-endorphin increases serum prolactin, but not growth hormone or cortisol, in depressed subjects and withdrawing methadone addicts. J. Clin. Endocrinol. Metab. 50 (1980) 1021-1025
19. Chong R.Y., Oswald L., Yang X., Uhart M., Lin P.I., and Wand G.S. The mu-opioid receptor polymorphism A118G predicts cortisol response to naloxone and stress. Neuropsychopharmacology 31 (2006) 204-211
20. Crockett C.M., Sackett G.P., Sandman C.A., Chicz-DeMet A., and Benston K.L. Beta-endorphin levels in longtailed and pigtailed macaques vary by abnormal behavior rating and sex. Peptides 28 (2007) 1987-1997
21. DeHaven-Hudkins D.L., Burgos L.C., Cassel J.A., Daubert J.D., DeHaven R.N., Mansson E., Nagasaka H., Yu G., and Yaksh T.L. Loperamide (ADL-2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J. Pharmacol. Exp. Ther. 289 (1999) 494-502
22. Dent R.R.M., Guilleminault C., Albert L.H., Posner B.I., Cox B.M., and Goldstein A. Diurnal rhythms of plasma immunoreactive beta-endorphin and its relationship to sleep stages and plasma rhythms of cortisol and prolactin. J. Clin. Endocrinol. Metab. 52 (1981) 942-947
23. Domino E.F., and Li C.H. Beta-endorphin suppression of acute morphine abstinence in morphine dependent monkeys: effective given intraventricularly but ineffective given intravenously. Neuropeptides 6 (1985) 343-350
24. Foley K.M., Kourides I.A., Inturrisi C.E., Kaiko R.F., Zaroulis C.G., Posner J.B., Houde R.W., and Li C.H. beta-Endorphin: analgesic and hormonal effects in humans. Proc. Natl. Acad. Sci. USA 76 (1979) 5377-5381
25. Fortman J.D., Hewett T.A., and Bennett B.T. The Laboratory Nonhuman Primate (2002), CRC, Boca Raton, FL
26. France C.P., and Gerak L.R. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J. Pharmacol. Exp. Ther. 270 (1994) 992-999
27. Gerak L.R., Butelman E.R., Woods J.H., and France C.P. Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. J. Pharmacol. Exp. Ther. 271 (1994) 993-999
28. Gilbeau P.M., Almirez R.G., Holaday J.W., and Smith C.G. Opioid effects on plasma concentrations of luteinizing hormone and prolactin in the adult male rhesus monkey. J. Clin. Endocrinol. Metab. 60 (1985) 299-305
29. Heykants J., Michiels M., Knaeps A., and Brugmans J. Loperamide (R18553), a novel type of antidiarrheal agent. Part 5: The pharmacokinetics of loperamide in rats and man. Arzneimittelforschung 24 (1974) 1649-1653
30. Hoehe M., Duka T., and Doenicke A. Human studies on the mu opiate receptor agonist fentanyl: neuroendocrine and behavioral responses. Psychoneuroendocrinology 13 (1988) 397-408
31. Kalin N.H., Rish S.C., Insel T.R., and Murphy D.L. Dexamethasone fails to suppress beta-endorphin plasma concentrations in humans and rhesus monkeys. Science 209 (1980) 827-828
32. Kenakin T. Pharmacologic Analysis of Drug Receptor Interaction. second ed. (1993), Raven Press, New York
33. Ko M.C., Terner J., Hursh S., Woods J.H., and Winger G. Relative reinforcing effects of three opioids with different durations of action. J. Pharmacol. Exp. Ther. 301 (2002) 698-704
34. Kreek M.J., Wardlaw S.L., Hartman N., Raghunath J., Friedman J., Schenider B., and Frantz A.G. Circadian rhythms and levels of beta-endorphin, ACTH and cortisol during chronic methadone maintenance treatment in humans. Life Sci. 33 Suppl. I (1983) 409-411
35. Lehmann H., Nair N.P., and Kline N.S. beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects. Am. J. Psychiatry 136 (1979) 762-766
36. Lotsch J., Skarke C., Liefhold J., and Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin. Pharmacokinet. 43 (2004) 983-1013
37. Mansour A., Hoversten M.T., Taylor L.P., Watson S.J., and Akil H. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. 700 (1995) 89-98
38. Manzanares J., Wagner E.J., Lookingland K.J., and Moore K.E. Effects of immunoneutralization of dynorphin1-17 and dynorphin1-8 on the activity of central dopaminergic neurons in the male rat. Brain Res. 587 (1992) 301-305
39. Merchenthaler I. Neurons with access to the general circulation in the central nervous system of the rat: a retrograde tracing study with fluoro-gold. Neuroscience 44 (1991) 655-662
40. Miller G.M., Bendor J., Tiefenbacher S., Yang H., Novak M.A., and Madras B.K. A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression. Mol. Psychiatry 9 (2004) 99-108
41. Moore K.E., and Lookingland K.J. Dopaminergic neuronal systems in the hypothalamus. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 245-256
42. Odio M., and Brodish A. Central but not peripheral opioid receptor blockade prolonged pituitary-adrenal response to stress. Pharmacol. Biochem. Behav. 35 (1990) 963-969
43. Panerai A.E., Casanueva F., Martini A., Mantegazza P., and DiGiulio A.M. Opiates act centrally on GH and PRL release. Endocrinology 108 (1981) 2400-2402
44. Pechnik R.N., George R., and Poland R.E. The effects of systemic administration of n-methylmorphine chloride, a quaternary analogue of morphine that does not cross the blood-brain barrier, on the release of anterior pituitary hormones in the rat. Psychoneuroendocrinology 12 (1987) 67-71
45. Pecins-Thompson M., Brown N.A., Kohama S.G., and Bethea C.L. Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J. Neurosci. 16 (1996) 7021-7029
46. Remmers A.E., Clark M.J., Mansour A., Akil H., Woods J.H., and Medzihradsky F. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. J. Pharmacol. Exp. Ther. 288 (1999) 827-833
47. Rittner H.L., Brack A., Machelska H., Mousa S.A., Bauer M., Schafer M., and Stein C. Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology 95 (2001) 500-508
48. Rowland M., and Tozer T.N. Clinical Pharmacokinetics: Concepts and Application (1980), Lea & Febiger, Philadelphia
49. Sandin J., Nylander I., and Silberring J. Metabolism of beta-endorphin in plasma studied by liquid chromatography-electrospray ionization mass spectrometry. Regul. Pept. 73 (1998) 67-72
50. Sato H., Sugiyama A., Sawada Y., Iga T., and Hanano M. Binding of radioiodinated human beta-endorphin to serum proteins from rats and humans, determined by several methods. Life Sci. 37 (1985) 1309-1318
51. Sato H., Sugiyama Y., Sawada Y., Iga T., and Hanano M. Physiologically based pharmacokinetics of radioiodinated human beta-endorphin in rats. An application of the capillary membrane-limited model. Drug. Metab. Dispos. 15 (1987) 540-550
52. Schulz A., Harbach H., Katz N., Geiger L., and Teschemacher H. beta-Endorphin immunoreactive material and authentic beta-endorphin in the plasma of males undergoing anaerobic exercise on a rowing ergometer. Int. J. Sports Med. 21 (2006) 513-517
53. Selley D.E., Sim L.J., Xiao R., Liu Q., and Childers S.R. mu-Opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol. Pharmacol. 51 (1997) 87-96
54. Simpkins J.W., Swager D., and MIllard W.J. Evaluation of the sites of opioid influence on anterior pituitary hormone secretion using a quaternary opioid antagonist. Neuroendocrinology 54 (1991) 384-390
55. Spies H.G., Quadri S.C., Chappel S.C., and Norman R.L. Dopaminergic and opioid compounds. Effects on prolactin and LH release after electrical stimulation of the hypothalamus in ovariectomized rhesus monkeys. Neuroendocrinology 30 (1980) 249-256
56. Thornton J.R., and Losowsky M.S. Plasma beta-endorphin in cirrhosis and renal failure. Gut 32 (1997) 306-308
57. Wardlaw S.L., Wehrenberg W.B., Ferin M., and Frantz A.G. Failure of beta-endorphin to stimulate prolactin release in the pituitary stalk-sectioned monkey. Endocrinology 107 (1980) 1663-1666
58. Wiedemann E., Saito T., Linfoot J.A., and Li C.H. Specific radioimmunoassay of human beta-endorphin in unextracted plasma. J. Clin. Endocrinol. Metab. 49 (1979) 478-480
59. Yanagita T., Miyasato K., and Sato J. Dependence potential of loperamide studied in rhesus monkeys. NIDA Res. Monogr. 27 (1979) 106-113
60. Zheng S.X., Bosch M.A., and Ronnekleiv O.K. mu-Opioid receptor mRNA expression in identified hypothalamic neurons. J. Comp. Neurol. 487 (2005) 332-344
61. Zhu J., Luo L.Y., Li J.G., Chen C., and Liu-Chen L.Y. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J. Pharmacol. Exp. Ther. 282 (1997) 676-684